What Happened

Lycia Therapeutics went public on Nasdaq under ticker LYCA, raising $317.5 million after an upsized offering of 17.6 million shares at $18 each. Shares closed the first day up nearly 67% at $30. Separately, Swiss biotech Windward Bio filed for an IPO, though pricing and share count have not been disclosed.

Who Is Affected

Lycia’s workforce of 31 full-time employees now manages over $300 million in new capital. The company has earmarked ~$80M for a phase 2 study of LCA-0061, $70M for LCA-0062, and $90M for LCA-0321—creating immediate needs for clinical trial management, regulatory compliance, and data management tools. Windward Bio, with its own IPO filing, will similarly scale operations for phase 2/3 trials in COPD and asthma.

Market Impact

The strong IPO reception signals renewed investor confidence in biotech, potentially accelerating the funding window for other private companies. For vendors serving clinical-stage biotechs, this dual IPO event highlights a period of rapid operational expansion and procurement activity.

• Lycia’s stock performance may encourage more IPOs, increasing the pool of potential buyers.
• Both companies are advancing pipeline assets into costly late-stage trials, driving external vendor spend.

What to Watch

Lycia’s phase 1 data for LCA-0061 showed rapid IgE reduction—phase 2 enrollment will be a key milestone. Windward Bio’s IPO pricing and timeline will determine its capital position for phase 2b and 3 trials. SDRs should monitor vendor contracts and project announcements from both companies in the coming weeks.

Related coverage

• Lycia Therapeutics targets $228M IPO to fund protein degrader pipeline for food allergy
• Ambrose Healthcare acquires AM-Pharma for up to $181M
• Novartis pays $575M upfront for Abogen's mRNA T-cell engager ABO2203
• Scholar Rock secures FDA approval for SMA treatment apitegromab (Isembyld)